We have some 29 companies on our watchlist, all in a variety of sectors, that we’re covering at any one time. Some are clients, some not, some are on…
MDP.V
There are many cases in today’s market of investors allowing their mob mentality to inefficiently price securities in the public auction market. Sir John Templeton, speaking on market volatility…
“Medicine is a science of uncertainty and an art of probability.” – William Osler I think it’s appropriate I start the article by saying that I get it, biotech…
Medexus Pharmaceuticals (MDP.V) announced that they’re making their Triamcinolone Hexacetonide (TH) Injectable Suspension, USP (20 mg/ml) available in the United States through the FDA’s CDER Drug Shortage program in…
Medexus common stock reached a high of $7.70 per share due to a positive market reaction to their latest press release. At a time where the general economy and…
Buckle up everyone, and get excited – let’s break down Medexus’ latest press release with all its technical details. This is a two-parter, because Medexus not only has closed…
If you are like me and health sciences is your sector of choice when it comes to investing in the markets, you’d better be very patient, love doing research…
Vancouver media personality, Jody Vance, took time to talk with Medexus Pharmaceuticals (MDP.V) CEO and director Ken d’Entremonet to get a better look at the company’s specialty pharma portfolio…
Before the Orphan Drug Act was introduced in 1983, Big Pharma ignored rare diseases, leaving people suffering from chronic conditions such as cancer, hemophilia and H.I.V., to fend for…
Everyone has that one friend that’s into the weird shit. I don’t mean strange drugs or alcohol (but I don’t not mean that either), but strange cultural esoterica like…